Silvant Capital Management LLC Acquires 2,186 Shares of Insulet Corporation $PODD

Silvant Capital Management LLC boosted its holdings in Insulet Corporation (NASDAQ:PODD) by 17.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,935 shares of the medical instruments supplier’s stock after purchasing an additional 2,186 shares during the quarter. Silvant Capital Management LLC’s holdings in Insulet were worth $4,611,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in PODD. True Wealth Design LLC increased its position in Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 43 shares in the last quarter. Quent Capital LLC bought a new position in Insulet in the 3rd quarter worth about $49,000. Osterweis Capital Management Inc. purchased a new stake in Insulet during the 2nd quarter valued at about $51,000. Finally, Zions Bancorporation National Association UT raised its holdings in Insulet by 57.3% in the third quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 63 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PODD shares. TD Cowen cut shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target on the stock. in a report on Monday, January 26th. Citigroup cut their target price on Insulet from $380.00 to $345.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Royal Bank Of Canada boosted their price target on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Oppenheimer lowered their target price on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Finally, Barclays reissued an “underweight” rating and set a $286.00 price objective on shares of Insulet in a report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $354.57.

Insulet Trading Down 0.9%

Insulet stock opened at $238.24 on Wednesday. Insulet Corporation has a 52-week low of $233.29 and a 52-week high of $354.88. The company has a market cap of $16.77 billion, a P/E ratio of 68.07, a P/E/G ratio of 1.43 and a beta of 1.42. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The business has a 50-day simple moving average of $261.60 and a two-hundred day simple moving average of $298.92.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.07. The firm had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.15 EPS. Analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.